Ocular Therapeutix, Inc.

OCUL Healthcare Biotechnology

Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024.

Revenue
+0.12%
EPS
+10.3%
Free cash flow
−25.4%
Total debt
+4.13%

Quarter to June 2026, against a year earlier

6.62 0.19 +2.95%
Market cap
$1.4B
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
4/9
Altman Z
6.91
Beneish M
−2.92
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 4 2

+8 more TTM periods

ROE
(72.99%) (68.55%) (54.85%) (81.83%)
ROA
(53.70%) (51.03%) (42.01%) (55.41%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(49.04%) (42.93%) (35.41%) (70.40%)
Average Days of Receivables
212.19 170.77 215.34 201.32
Free Cash Flow per Share
(1.13) (1.07) (1.16) (1.08)
Free Cash Flow
(255.10) (240.81) (216.76) (199.31)
Other line items

Show all line items

Columns are period end dates